SCHEMBL23207905

SCHEMBL23207905

CC(=O)c1cccc(-c2ccc3[nH]cc(NC(=O)Nc4ccc(C(F)(F)F)cc4)c3c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 10/20 0.63
▸ BAZ1A Q9NRL2 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ EPHX2 P34913 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ RIPK1 Q13546 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ CHEK2 O96017 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ CSF1R P07333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30196153 1.00 STING1 (0.63) STING1BAZ1AMTOREPHX2MAPT
SCHEMBL23167861 0.89 STING1 (0.73) STING1EPHX2MAPTMEN1HTT
SCHEMBL30195880 0.88 STING1 (0.65) STING1BAZ1AMTOREPHX2MAPT
SCHEMBL23208060 0.88 STING1 (0.65) STING1BAZ1AMTOREPHX2MAPT
SCHEMBL23208067 0.88 STING1 (0.65) STING1EPHX2MAPTMEN1HTT
SCHEMBL30196046 0.88 STING1 (0.65) STING1EPHX2MAPTMEN1HTT
SCHEMBL23207916 0.87 STING1 (0.64) STING1BAZ1AMTOREPHX2MAPT
SCHEMBL23208191 0.86 STING1 (0.61) STING1MAPTMEN1HTTRAB9A
SCHEMBL23207645 0.86 STING1 (0.61) STING1BAZ1AMTOREPHX2MAPT
SCHEMBL30196128 0.86 STING1 (0.61) STING1BAZ1AMTOREPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885BAZ1A 1991/4885MTOR 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback